Viking Therapeutics, Inc.（VKTX）在今日夜盘交易中股价大涨9.91%，引起了市场的广泛关注。
消息面上，公司宣布计划在今年第三季度将其试验性口服肥胖症药物VK2735推进到后期试验阶段。公司认为，同时提供口服和注射剂型是VK2735区别于竞争药物的重要优势，因为目前尚无其他同类药物同时提供这两种剂型。中期研究数据显示，VK2735口服片剂每日一次，在13周后帮助患者平均体重下降达12.2%。
这一进展被视为公司在肥胖症治疗领域的重要里程碑，增强了投资者对其药物商业化前景和未来增长潜力的信心，从而推动了股价在夜盘时段的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.